Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma

Gynecol Oncol. 2021 Jun;161(3):645-652. doi: 10.1016/j.ygyno.2021.03.017. Epub 2021 Mar 29.

Abstract

A 73-year-old woman with metastatic vaginal mucosal melanoma that had progressed on ipilimumab and nivolumab experienced clinical and radiographic complete response to dual checkpoint inhibitor immunotherapy given in combination with high-dose plus low-dose radiation. General characteristics and treatment options in this disease are highlighted.

Keywords: Abscopal effect; Immunotherapy; Low dose radiation; Vaginal mucosal melanoma.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / therapeutic use
  • Combined Modality Therapy
  • Drug Therapy, Combination
  • Female
  • Humans
  • Ipilimumab / administration & dosage
  • Ipilimumab / therapeutic use
  • Melanoma / diagnostic imaging
  • Melanoma / secondary
  • Melanoma / therapy*
  • Mucous Membrane / pathology
  • Neoplasm Metastasis
  • Nivolumab / administration & dosage
  • Nivolumab / therapeutic use
  • Radiotherapy
  • Urethral Neoplasms / diagnostic imaging
  • Urethral Neoplasms / secondary
  • Urethral Neoplasms / therapy*
  • Vaginal Neoplasms / diagnostic imaging
  • Vaginal Neoplasms / pathology
  • Vaginal Neoplasms / therapy*

Substances

  • Antineoplastic Agents, Immunological
  • Ipilimumab
  • Nivolumab